LF1
LF1 is a gastrin-releasing peptide receptor (GRPR) antagonist. LF1 can be stably radiolabeled with gallium-68, indium-111, and lutetium-177. Radiolabeled LF1 can be used for high-contrast SPECT/CT imaging. LF1 is applicable to prostate cancer-related research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C80H119N19O21
- Peso molecular:1682.92
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Radionuclide-Drug Conjugates (RDCs)
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
RDC Peptide |
In Vitro
The combination strategy of Rapamycin (HY-10219) and Lutetium-177-labelled LF1 (72 h) reduces the viability of PC3 cells more effectively than either agent used alone, with cell viability decreasing to approximately 40% at 72 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human prostate adenocarcinoma PC3 cells
-
Concentration:1.85 MBq lutetium-177-labelled LF1
-
Incubation Time:72 h
-
Result:Resulted in ~70% cell viability at 72 h for lutetium-177-labelled LF1 monotherapy.
Resulted in ~50% cell viability at 72 h for rapamycin monotherapy.
Resulted in ~40% cell viability at 72 h for combination therapy with rapamycin and lutetium-177-labelled LF1.
In Vivo
Combination therapy with a single dose of [177Lu]Lu-LF1 (40 MBq) and pretreatment with Everolimus (HY-10218) enhances tumor control in PC-3 tumor-bearing mice and prolongs their median survival to 38 days, whereas a single dose of [177Lu]Lu-LF1 alone yields no significant benefit[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/C nude (male, 6 weeks old, 20-25 g, subcutaneously implanted with PC-3 cells)[1]
-
Dosage:41.2 MBq (1200 pmol total, 6 fractional doses); 93.4 MBq (2400 pmol total, 6 fractional doses)
-
Administration:6 fractional doses over two 3-day periods separated by a 1-week interval
-
Result:Showed limited tumor control and reached study end points within 25 days, with a median survival of 16 days (41.2 MBq dose).
Exhibited significant tumor suppression, with tumor volumes remaining under 400 mm3 for at least the first 25 days, and had a median survival of 50 days, with two mice surviving past 104 and 127 days (93.4 MBq dose).
Remained stable across all treated groups (body weight).
Chemical Information
-
Peso molecular 1682.92
-
Fòrmula C80H119N19O21
-
Sequence
{AAZTA-Pip-d-Phe}-Gln-Trp-Ala-Val-Gly-His-{Sta}-Leu-NH2
-
Sequence Shortening
{AAZTA-Pip-d-Phe}-QWAVGH-{Sta}-L-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LF1 Related Classifications
HY-P11917 Related Classifications
Powered by Bioz